Original Article
Relationship of HbA1c with
Visual and Anatomical Outcomes of Bevacizumab in Diabetic Macular Edema
Royala
Zaka, Yasir Khan, Burhan Abdul Majid Khan, Mirza Zaki-ud-Din Ahmed Sabri, Rabia
Qureshi
DOI 10.36351/pjo.v35i4.937 Pak J Ophthalmol 2019, Vol. 35, No. 4
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See end of article for authors affiliations …..……………………….. Correspondence to: Dr. Royala Zaka Consultant Ophthalmologist Prevention of Blindness (POB), Karachi, Pakistan Email: drroyala@hotmail.com |
Purpose: To find relationship of
baseline Hemoglobin A1c (HbA1c) with visual outcomes, central macular
thickness and number of intravitreal Bevacizumab at 12 months in patients
with diabetic macular edema (DME). Study Design: Quasi
experimental study. Place and Duration of Study: Prevention
of blindness (POB) Hospital, Karachi, Pakistan between October 2018 and
September 2019. Material and Methods: Two hundred and eighty patients
with Diabetic macular edema (DME) presenting to the eye OPD of POB, who did
not receive any treatment for DME were recruited. Patients who had concurrent
retinal disease and were treated with intravitreal injections and/or laser
were excluded. All patients were
evaluated with history, ophthalmological examination and SD-OCT for
central subfield macular thickness. Patients received 3 intravitreal
injections of Bevacizumab one month apart. OCT was done after 3 months and
retreatment for diabetic macular edema was based on the persistence of
macular thickness more than 300 microns. All the data was analyzed using SPSS
version 20. Results: There
were 280 patients, 53.2% were males and 46.8% were
females. Patients were divided into 3 groups; patients with HbA1C
< 7.0, 7.1 – 8.0 and Conclusion: Initial baseline HbA1C is strongly related with
visual and anatomic outcome at 12 months. Key
Words: Diabetic macular edema; Bevacizumab; Hemoglobin A1C. |
Approximately 21 million people are affected by diabetic macular
edema worldwide1. By 2025, the incidence of diabetes in Pakistan
will get doubled2. The high burden of
diabetic complications is associated with uncontrolled diabetes3. Therefore,
control of diabetes is the main pillar for prevention and delaying of diabetic
complications. In diabetes mellitus, the main reason of visual loss is
macular edema4. Evidence shows that diabetic macular edema and
moderate visual loss can be reduced by tight glycemic control5. The Royal
College of Ophthalmologists’ Clinical Guidelines for Diabetic Retinopathy”
recommends laser alone6.
Until recently, macular photocoagulation was the treatment of choice for
diabetic macular edema. Even with this treatment, macular edema persists in the
presence of uncontrolled diabetes7.
The entire treatment picture has changed with the introduction of anti-vascular
endothelial growth factors especially for DME8.
Not only we have seen the relationship of HbA1C with
visual and anatomical outcome like previous studies, but also seen the
relationship of baseline HbA1C with frequency or number of Anti-VEGF
injections in diabetic macular edema. The frequency of Anti-VEGF injections is
an important aspect to know as in the developing country like Pakistan, the
cost is one of the main issues. The
rationale of our study was that patients with baseline lower HbA1C may have better visual and anatomical
outcome and may require fewer number of Anti-VEGF injections in one duration as
compared with patients having high baseline HbA1C.
The purpose of our study was to find relationship of baseline
Hemoglobin A1c (HbA1c) with visual outcomes, central macular thickness and
number of intravitreal Bevacizumab at 12 months in patients with diabetic
macular edema (DME).
MATERIAL AND METHODS
This study was done between October 2018
to September 2019 at Prevention of Blindness, a charity based hospital where
approximately 100 patients receive Anti-VEGF injections weekly for different
ocular conditions. Ethical approval was taken before the start of study.
Two hundred and eighty patients
diagnosed with diabetic macular edema with initial HbA1C
of less than or more than 7.0, who
received at least three Anti-VEGF injections were recruited for the study. They
were followed up for 12 months. The exclusion criteria of our study was those individuals
who had concomitant retinal disease or who had macular edema due to reasons
other than diabetes or had previous treatment with pan-retinal
photocoagulation or macular photocoagulation or macular ischemia or did
not have baseline HbA1C
or those who were lost to follow-up.
All patients were evaluated starting
from the history and comprehensive ophthalmological examination that included
best corrected visual acuity using Snellen chart, biomicroscopy to diagnose clinically significant macular edema and OCT optical coherence tomography (SD-OCT) with a central
subfield macular thickness (CSMT) measurement to quantify, document and follow-up
the macular thickness. The patients whose visual acuity was affected by
disruptive anatomy of macula due to the intracystic spaces involving the macula
or had more than 300 micron macular thickness on OCT were given intravitreal
injections of Bevacizumab. Patients received 3 intravitreal injections at one-month
interval. OCT was done after 3 months and retreatment for diabetic macular edema
was based on the persistence of macular thickness more than 300 microns.
Patients were followed monthly and HbA1C was recorded 3
to 4 monthly interval until 12 months. Consent was taken from all the patients
after brief explanation about the study, treatment and follow-up. All the data
was entered in SPSS version 20, Paired t-test, test of proportion and Pearson
correlation coefficient were used for statistical analysis.
RESULTS
Out of 280 patients, 149 (53.2%) were males and 131 (46.8%) were
females. Twenty (7.1%) patients had HbA1C of < 7.0, 187 (66.8%)
had 7.1-8.0 and 73 (26.1%) patients had > 8.0 HbA1c (Table1). Central
macular thickness was significantly decreased on 12 months from baseline (p <
0.01). Number of injections given were more according to HbA1c (<
7.0, 7.1 – 8.0 and > 8.0) but statistically not significant (p > 0.05).
Increase in visual acuity was more in patients with HbA1c of < 7.0 as
compared to the patients with higher HbA1C (Table 2). Initial
baseline HbA1C was strongly related with visual and anatomic outcome
at 12 months.
Table
1: Demographic characteristics (n = 280).
|
Frequency |
Percent |
Gender |
||
Male |
149 |
53.2 |
Female |
131 |
46.8 |
Age in years |
|
|
Under 50 |
27 |
9.6 |
50-59 |
158 |
56.4 |
60 & above |
95 |
33.9 |
Range |
44–73 |
|
Mean ± S.D |
58.1 ± 6.11 |
|
HbA1c |
||
Group 1 (HbA1c ≤ 7.0) |
20 |
7.1 |
Group 2 (HbA1c 7.1-8.0) |
187 |
66.8 |
Group 3 (HbA1c > 8.0) |
73 |
26.1 |
Table
2: Comparison of HbA1c with CMT, Number of injection and Visual status.
HbA1c <=7.0 (n=20) n, Mean ± S.D |
HbA1c 7.1-8.0 (n=187) n, Mean ± S.D |
HbA1c > 8.0 (n=73) n, Mean ± S.D |
|
HbA1c |
|||
Base line (Day 0) |
19, 6.93 ± 0.09 |
163, 7.49 ± 0.25 |
67, 9.37 ± 1.24 |
At 12 months |
19, 7.17 ± 0.31 |
163, 7.38 ± 0.44 |
67, 8.64 ± 1.43 |
P-value |
0.005 |
0.003 |
0.001 |
Duration of DM (Years) |
20, 10.0 ± 2.51 |
180, 13.7 ± 4.71* |
73, 16.4 ± 4.46* º |
CMT Right |
|||
Base line (Day 0) |
19, 365 ± 72.1 |
161, 353 ± 81.7 |
67, 424 ± 138.4 |
At 12 months |
19, 287 ± 315 |
161, 302 ± 60.1 |
67, 378 ± 135.3 |
P-value |
0.001 |
0.001 |
0.001 |
CMT Left |
|||
Base line (Day 0) |
19, 292 ± 44.4 |
159, 324 ± 70.7 |
67, 389 ± 118.7 |
At 12 months |
19, 272 ± 33.6 |
159, 294 ± 47.8 |
67, 357 ± 103.2 |
P-value |
0.043 |
0.001 |
0.001 |
Number of injections used in 12 months |
|||
Right |
6, 6.67 ± 2.16 |
87, 7.39 ± 1.49 |
52, 7.94 ± 1.29 |
Left |
2, 10.00 ± 0.00 |
62, 8.19 ± 1.04 |
44, 8.20 ± 1.30 |
Vision increased on 12 months |
|||
Right |
16 (94%) out of 17 1 Line 6 (35%) 2 Line 9 (53%) 3 Line 1 (6%) |
73 (64%) out of 113 * 1 Line 23 (20%) 2 Line 34 (30%) 3 Line 15 (13%) 4 Line 1 (1%) |
24 (41%) out of 59 * º 1 line 13 (22%) 2 line 7 (12%) 3 line 3 (5%) 4 line 1 (2%) |
Left |
5 (83%) out of 6 3 line 5 (83%) |
60 (68%) out of 88* 1 Line 31 (35%) 2 Line 20 (23%) 3 Line 9 (10%) |
18 (36%) out of 50 * 1 line 12 (24%) 2 line 2 (4%) 3 line 4 (8%) |
Significant from HbA1c
<= 7.0 *P < 0.05 Significant
from HbA1c 7.1 – 8.0 ºP < 0.05
DISCUSSION
Our study showed that baseline HbA1c has
positive correlation with baseline CMT (r = 0.53, p < 0.01) that means if
the initial HbA1c is uncontrolled, patients can have high central macular thickness
(CMT). We found that in
patients with < 7.0, 7.1 to 8.0 and > 8.1 Hba1c, CMT decreased in all patients
after Anti-VEGF injections. Our results also correspond to the previous studies
in which the patients having low HbA1C showed greater visual improvement with
the use of Anti-VEGF injections9. Matsuda and colleagues showed that with HbA1C of
7.0 or less there was significant decrease in CMT with the use of Bevacizumab
and similar results were seen with the use of another Anti-VEGF Ranibizumab10,11.
Diabetic Retinopathy Research Group Vienna also showed that CMT was
decreased at its maximum by using either Bevacizumab or Ranibizumab if the HbA1C
was less than 7.012.
Diabetic macular edema is the biggest
cause of visual loss in diabetic retinopathy and can happen at any stage of diabetic
retinopathy13. Tight glycemic
control < 7.0 can delay or prevent the complications in both type 1 and type
2 diabetes14,15.
However VIVID and VISTA DME studies showed that there was no
relationship of baseline HbA1C with visual and anatomical outcome. The
difference in results might be because the Anti-VEGF used was Aflibercept and
less or more than 8.0 HbA1C was used in the study16.
According to Matsuda et al DME with
regulated blood glucose can impact the response to Bevacizumab. The patients
with a starting HbA1C of 7.0 or less showed more improvement in BCVA during the 12 months of
therapy than those with starting HbA1C > 7.09. Pemp and
colleagues also described that the visual improvement could be gained at its
highest level by using Bevacizumab or Ranibizumab if the baseline HbA1C was < 7.0 at the start of
therapy12.
Pakistan is a developing country where
cost matters for everything and same is for the Ani-VEGF injections. Bevacizumab
being a cost effective injection could be the reason for the increased number
of injections used in our study. We did not compare among different Anti-VEGF
injections like Ranibizumab or Aflibercept that might have given results at a
lower number of injections as compared with Bevacizumab which is commonly used
in our set up. An article showed that bevacizumab in relation with cost
effectiveness is superior to other Anti-VEGF injections17. Another
study showed that the cost of Ranibizumab is 20 to 40 folds higher than the
cost of Bevacizumab and the treatment of DME is 10 to 15 million Euros higher
in Netherland18. The Bevacizumab is the cost effective choice as
compared to Ranibizumab and Aflibercept19. The other reason of increase number of injections
in the group having < 7.0 HbA1C might be the increase in its HbA1C until 12
months.
The DRCR.net compared the efficacy of 3Anti-VEGF
at 2 years. Vision improved in all 3 drug groups however, the frequency of
injections became half in 2nd year20. Our follow up was only
1 year so future studies can check this frequency of injections for more than a
year.
One study showed that despite different levels of glycemic control
during the treatment the baseline HbA1C
affects the visual and anatomical outcome however, the required number
of Anti-VEGF injections decrease during the course of treatment if the HbA1C remains controlled4.
Limitation of
our study was the small number of patients and it was a retrospective study. There
were also lesser number of patients in group 1. Future studies can be planned
to investigate this group further. Only Bevacizumab was used in this study.
Other Anti-VEGF like Ranibizumab and Aflibercept can be compared with
Bevacizumab in future studies.
CONCLUSION
Baseline HbA1C has a strong relation with visual and anatomic
outcome in diabetic macular edema.
REFERENCES
1. Bansal AS, Khurana RN, Wieland MR, Wang
P-W, Van Everen SA, Tuomi L. Influence of glycosylated hemoglobin on the
efficacy of ranibizumab for diabetic macular edema: a post hoc analysis of the
RIDE/RISE trials. Ophthalmology, 2015; 122 (8): 1573-9.
2. Mumtaz SN, FahimMF, Arslan M, Shaikh SA, Kazi U, Memon MS. Prevalence of diabetic retinopathy in Pakistan; A systematic
review. Pak J Med Sci. 2018; 34 (2): 493–500.
3. Fasil A, Biadgo B, Abebe M. Glycemic
control and diabetes complications among diabetes mellitus patients attending
at University of Gondar Hospital, Northwest Ethiopia. Diabetes, metabolic
syndrome and obesity: targets and therapy.Diabetes Metab Syndr Obes. 2019;
12: 75–83.
5. Chew EY, Davis MD, Danis RP, Lovato JF,
Perdue LH, Greven C, et al. The effects of medical management on the
progression of diabetic retinopathy in persons with type 2 diabetes: the Action
to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014;
121 (12): 2443-51.
6. Jafri
AS, Aziz-ur-Rehman AHM, Memon S. Outcomes of intravitreal bevacizumab and
macular photocoagulation for treatment of diabetic macular edema in a tertiary
care eye hospital, Karachi. Pak J Med Sci. 2017; 33 (5): 1215.
7. Do DV, Shah SM, Sung JU, Haller JA, Nguyen
QD. Persistent diabetic macular edema is associated with elevated
hemoglobin A1C. American journal of Ophthalmology, 2005; 139 (4): 620-3.
8. Ajlan RS, Silva PS, Sun JK. Vascular
endothelial growth factor and diabetic retinal disease. Semin Ophthalmol. 2016;
31 (1-2): 40-8.
9. Singh
RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I. The Impact of Systemic Factors on
Clinical Response to Ranibizumab for Diabetic Macular Edema.
Ophthalmology, 2016; 123 (7): 1581-7.
10. Matsuda S, Tam T, Singh RP, Kaiser PK,
Petkovsek D, Carneiro G, et al. The impact of metabolic parameters on
clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications,
2014; 28 (2): 166-70.
11. Ozturk BT, Kerimoglu H, Adam M, Gunduz K,
Okudan S. Glucose regulation influences treatment outcome in ranibizumab
treatment for diabetic macular edema. J Diabetes Complications, 2011; 25 (5): 98-302.
12. Pemp B, Deak G, Prager S. Diabetic
Retinopathy Research Group Vienna Distribution of intraretinal exudates in
diabetic macular edema during anti-vascular endothelial growth factor therapy
observed by spectral domain optical coherence tomography and fundus
photography. Retina, 2014; 34 (12): 2407-15.
13. Midena E, Gillies M, Katz TA, Metzig C, Lu
C, Ogura Y. Impact of Baseline Central Retinal Thickness on Outcomes in the
VIVID-DME and VISTA-DME Studies. J Ophthalmol. 2018; 29: 3640135.
14. Nathan DM, McGee P, Steffes MW, Lachin JM,
group DEr. Relationship of glycated albumin to blood glucose and HbA1c values
and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC
study. Diabetes, 2014; 63 (1): 282-90.
15. Clarke
PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to
estimate the lifetime health outcomes of patients with type 2 diabetes: the
United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no.
68). Diabetologia. 2004; 47
(10): 1747-59.
16. Singh
RP, Wykoff CC, Brown DM, Larsen M, Terasaki H, Silva FQ, et al. Outcomes of
diabetic macular edema patients by baseline hemoglobin A1c: analyses from VISTA
and VIVID. Ophthalmology Retina, 2017; 1 (5): 382-8.
17. Heier
JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, et al. Comparison
of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular
edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016; 134 (1):
95-9.
18. Schauwvlieghe
AME, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MGW, et al. Comparing
the effectiveness and costs of bevacizumab to ranibizumab in patients with
diabetic macular edema: a randomized clinical trial (the BRDME study). BMC Ophthalmol.
2015; 15 (1): 71.
19. Ross
EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR.
Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic
macular edema treatment: analysis from the diabetic retinopathy clinical
research network comparative effectiveness trial. JAMA Ophthalmol. 2016; 134 (8):
888-96.
20. Wells
JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al.
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year
results from a comparative effectiveness randomized clinical trial.
Ophthalmology, 2016; 123 (6): 1351-9.
Author’s Affiliation
Dr. Royala Zaka
Consultant Ophthalmologist
Prevention of blindness (POB), Karachi, Pakistan
Dr. Yasir Khan
Consultant Ophthalmologist
Prevention of blindness (POB), Karachi, Pakistan
Dr. Burhan Abdul Majid Khan
Assistant Professor
Prevention of blindness (POB), Karachi, Pakistan
Dr. Mirza Zakiuddin Ahmed Sabri
Consultant Ophthalmologist
Prevention of blindness (POB), Karachi, Pakistan
Dr. Rabia Qureshi
Consultant Ophthalmologist
Prevention of blindness (POB), Karachi, Pakistan
Author’s Contribution
Dr. Royala Zaka
Study Design, data collection, manuscript
writing, final review
Dr. Yasir Khan
Critical revision, Final approval and
interpretation of data
Dr. Burhan Abdul Majid Khan
Critical revision, final review
Dr. Mirza Zakiuddin Ahmed Sabri
Critical revision, final review
Dr. Rabia Qureshi
Data collection, final review